Open Label Phase II Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2015
At a glance
- Drugs Tremelimumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 18 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 29 Dec 2009 New trial record